Physician profile
Rebecca Lynn Burke
NPI 1982031514
$11,710.38
in general payments reported to CMS, 2019-2025
27 companies · $3,335 in 2025
The $3,335 reported for 2025 was more than what 99% of Psychiatric/Mental Health, Child & Family providers received nationally (typical 2025 total: $178).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,602 · 2022: $1,315 · 2023: $2,397 · 2024: $3,061 · 2025: $3,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,785 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,785.17 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,734.57 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,177.73 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,142.48 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,006.77 | 2021-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $919.63 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $803.39 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Axsome Therapeutics, INC. | $633.85 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $574.24 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $549.92 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $526.13 | 2021-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $454.63 | 2022-2025 | Rexulti |
| Alkermes, INC. | $353.45 | 2021-2025 | Lybalvi, Aristada |
| Almatica Pharma LLC | $347.04 | 2021-2025 | Loreev Xr |
| Tris Pharma INC | $285.64 | 2023-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $284.70 | 2022-2024 | Jornay Pm |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $180.42 | 2021 | |
| Idorsia Pharmaceuticals US INC | $144.75 | 2022-2025 | Quviviq, Quviviq |
| Corium, LLC | $132.03 | 2022-2024 | Azstarys |
| Avanir Pharmaceuticals, INC. | $124.33 | 2021-2022 | |
| Noven Therapeutics, LLC | $87.58 | 2024 | Xelstrym, Secuado |
| Bausch Health US, LLC | $79.49 | 2021-2022 | |
| Eisai INC. | $39.81 | 2021 | |
| Collegium Pharmaceutical, INC. | $38.89 | 2025 | Jornay Pm |
| Biogen, INC. | $27.19 | 2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $26.95 | 2024 | Cobenfy |
| Jazz Pharmaceuticals INC. | $19.43 | 2021 | |
| Merck Sharp & Dohme LLC | $15.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.